Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394:121–130. https://doi.org/10.1016/S0140-6736(19)31149-3

Article  CAS  PubMed  Google Scholar 

Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 375:1834–1844. https://doi.org/10.1056/NEJMoa1607141

Article  CAS  PubMed  Google Scholar 

Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375:311–322. https://doi.org/10.1056/NEJMoa1603827

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wilding JPH, Batterham RL, Calanna S et al (2021) Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 384:989–1002. https://doi.org/10.1056/NEJMoa2032183

Article  CAS  PubMed  Google Scholar 

Lee JM, Sharifi M, Oshman L et al (2024) Dispensing of Glucagon-Like Peptide-1 Receptor Agonists to Adolescents and Young Adults, 2020–2023. JAMA 331:2041–2043. https://doi.org/10.1001/jama.2024.7112

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luo M, Cao Q, Wang D et al (2022) The impact of diabetes on postoperative outcomes following spine surgery: A meta-analysis of 40 cohort studies with 2.9 million participants. Int J Surg 104:106789. https://doi.org/10.1016/j.ijsu.2022.106789

Article  PubMed  Google Scholar 

Zhang X, Liu P, You J (2022) Risk factors for surgical site infection following spinal surgery: A meta-analysis. Med (Baltim) 101:e28836. https://doi.org/10.1097/MD.0000000000028836

Article  Google Scholar 

Steinmetz MP, O’Toole JE, Harrop JS et al (2025) Adverse Impact of Diabetes on Spine Fusion and Patient-Reported Outcomes. Spine 50:E347–E360. https://doi.org/10.1097/BRS.0000000000005396

Article  PubMed  PubMed Central  Google Scholar 

O’Toole JE, Sasso RC, Harrop JS et al (2025) Adverse Impact of Obesity on Lumbar Spine Fusion, Patient-reported Outcomes and Costs: A Systematic Review and Meta-analysis. Spine 50:1208. https://doi.org/10.1097/BRS.0000000000005395

Article  PubMed  PubMed Central  Google Scholar 

Karam L, Mabilleau G, Paccou J (2025) Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity. Osteoporos Int 36:2115–2126. https://doi.org/10.1007/s00198-025-07664-1

Article  PubMed  PubMed Central  Google Scholar 

Fang Q, Li G, Liu P et al (2025) GLP-1 and GIP: Magic bullet for musculoskeletal diseases? J Adv Res. https://doi.org/10.1016/j.jare.2025.08.046

Article  PubMed  PubMed Central  Google Scholar 

Zhang Y, Chen G, Wang W et al (2025) Association of Glucagon-like peptide-1 receptor agonists use with fracture risk in type 2 diabetes: A meta-analysis of randomized controlled trials. Bone 192:117338. https://doi.org/10.1016/j.bone.2024.117338

Article  CAS  PubMed  Google Scholar 

American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative. Accessed 17 Jan 2026

Kindel TL, Wang AY, Wadhwa A et al (2025) Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surg Endosc 39:180–183. https://doi.org/10.1007/s00464-024-11263-2

Article  PubMed  Google Scholar 

Kindel TL, Wang AY, Wadhwa A et al (2025) Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in the Perioperative Period. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 23:2083–2085. https://doi.org/10.1016/j.cgh.2024.10.003

Article  CAS  Google Scholar 

Most Patients Can Continue Diabetes Weight Loss GLP-1 Drugs Before Surgery, Those at Highest Risk for GI Problems Should Follow Liquid Diet Before Procedure. https://www.asahq.org/about-asa/newsroom/news-releases/2024/10/new-multi-society-glp-1-guidance. Accessed 17 Jan 2026

Abdulrazeq H, Taman M, Ali R et al (2024) GLP-1 Receptor Agonists: Beyond Diabetes-What the Neurosurgeon Needs to Know. Neurosurg Pract 5:e00098. https://doi.org/10.1227/neuprac.0000000000000098

Article  PubMed  PubMed Central  Google Scholar 

Barkyoumb D, Muhammad F, Smith ZA, Shakir HJ (2025) Preoperative optimization of obese spine patients with GLP-1 receptor agonists: enhancing surgery and improving outcomes. J Spine Surg Hong Kong 11:339–346. https://doi.org/10.21037/jss-24-152

Article  Google Scholar 

Connelly JW, Narayanan R, Ezeonu T et al (2025) Narrative Review of Perioperative Glucagon-like Peptide-1 (GLP-1) Agonists in Spine Surgery. Clin Spine Surg. https://doi.org/10.1097/BSD.0000000000001888

Article  PubMed  Google Scholar 

Younus I, Garcia de Oliveira R, Fujii T et al (2025) Are GLP-1 Receptor Agonists Safe in Spine Surgery: A Systematic Review. https://doi.org/10.1097/BRS.0000000000005466. Spine

Zahed M, Elmesalmi M, Al-Kharouf KF et al (2025) Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Spinal Fusion Outcomes: A Comprehensive Meta-Analysis. Cureus 17:e93065. https://doi.org/10.7759/cureus.93065

Article  PubMed  PubMed Central  Google Scholar 

Ononogbu-Uche FC, Toussaint F, Saleh AW et al (2026) Do GLP-1 agonists affect perioperative risk in spine surgery? A systematic review and meta-analysis. North Am Spine Soc J NASSJ. https://doi.org/10.1016/j.xnsj.2025.100835. 25:

Article  Google Scholar 

Fano A, Oris RJ, Dalton J et al (2025) GLP-1 Agonist Use Leads to Earlier Return of Bowel Function Following Lumbar Fusion. https://doi.org/10.1097/BRS.0000000000005598. Spine

Ghali A, Lawand J, Mitchell P et al (2025) The Use of Semaglutide in Patients Undergoing Lumbar Fusion Does not Increase 90-Day Medical or 1-Year Implant Complications. Clin Spine Surg 38:E579–E584. https://doi.org/10.1097/BSD.0000000000001800

Article  PubMed  Google Scholar 

Kesaria AA, Marzook FA, Glover JM, Alijanipour P (2025) Association Between Preoperative GLP-1 Receptor Analog Use and Postoperative Complications and Mortality Following Lumbar Fusion Surgery. Glob Spine J 21925682251391693. https://doi.org/10.1177/21925682251391693

Kishan A, Khela HS, Carayannopoulos NL et al (2025) Association of Glucagon-like Peptide-1 Receptor Agonist Use with Complications Following Thoracic and/or Lumbar Spinal Fusion for Degenerative Spine Disease: A BMI-Stratified Retrospective Study. https://doi.org/10.1097/BRS.0000000000005494. Spine

Seddio AE, Gouzoulis MJ, Vasudevan RS et al (2025) Semaglutide utilization associated with reduced 90-day postoperative complications following single-level posterior lumbar fusion for patients with type II diabetes. Spine J Off J North Am Spine Soc 25:485–493. https://doi.org/10.1016/j.spinee.2024.10.011

Article  Google Scholar 

Bank NC, Whittingslow D, Duggan S et al (2025) The Effect of GLP-1 Receptor Agonists on Reoperation Following Anterior Cervical Discectomy and Fusion. World Neurosurg 206:124751. https://doi.org/10.1016/j.wneu.2025.124751

Article  PubMed  Google Scholar 

Wiener JM, Sanghvi PA, Vlastaris K et al (2025) Glucagon-Like Peptide-1 Receptor Agonist Medications Alter Outcomes of Spine Surgery: A Study Among Over 15,000 Patients. Spine 50:871–880. https://doi.org/10.1097/BRS.0000000000005283

Article  PubMed  Google Scholar 

Stump K, Kelleher S, Hannah TC et al (2025) Perioperative Glucagon-like Peptide-1 Receptor Agonist Use Is Associated With Lower Pseudoarthrosis Rates Following Long-Segment Spinal Deformity Correction: A Propensity-Matched Analysis. Glob Spine J 21925682251396965. https://doi.org/10.1177/21925682251396965

Ng MK, Mastrokostas PG, Mastrokostas LE et al (2025) Semaglutide use is associated with higher rates of pseudarthrosis and dysphagia in patients undergoing posterior cervical fusion. Spine J Off J North Am Spine Soc 25:1974–1980. https://doi.org/10.1016/j.spinee.2025.03.023

Article  Google Scholar 

Ng MK, Mastrokostas PG, Rodriguez AN et al (2025) Semaglutide use before single-level lumbar fusion associated with fewer readmissions and 90-day costs. J Craniovertebral Junction Spine 16:401–407. https://doi.org/10.4103/jcvjs.jcvjs_156_25

Article  Google Scholar 

Vatsia SK, Levidy MF, Rowe ND et al (2025) Fusion Outcomes of GLP-1 Agonist Therapy in Multilevel Cervical Spinal Fusion: A Propensity-Matched Analysis. Clin Spine Surg 38:213–216. https://doi.org/10.1097/BSD.0000000000001775

Article  PubMed  Google Scholar 

Tummala S, Gibbs DC, Chavarria J et al (2025) GLP-1 receptor agonist use in elective lumbar spine surgery: Reduced pseudarthrosis rates and favorable safety profile. J Orthop 65:227–232. https://doi.org/10.1016/j.jor.2025.05.018

Article  PubMed  PubMed Central  Google Scholar 

Goldman SN, Mani K, Scharfenberger T et al (2025) Glucagon-like peptide-1 receptor agonist use prior to spinal surgery results in reduced postoperative length of stay: A propensity-score matched analysis. North Am Spine Soc J 22:100612. https://doi.org/10.1016/j.xnsj.2025.100612

Article  Google Scholar 

Kh